These multiple tumor sites were disproportionate between control and drug treatment cohorts during the treatment window, with three mice containing tumors in the bone within the control group and zero in the treatment group (Figure 5D), along with significant increases in E-cadherin expression despite no significant change in vimentin or survival with treatment of MTI-101 compared to the control (Figure 5B,E,F). The gene discussed is CDH1; the disease is neoplasm.